Publications by authors named "Guy Gammon"

Claim this Profile
C
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Siddhartha Ganguly, Jorge E Cortes, Alwin Krämer, Mark J Levis, Giovanni Martinelli, Guy Gammon

Transplant Cell Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Food on the Pharmacokinetics of Quizartinib.
Jianke Li, Melissa Holmes, Martin Kankam, Denise Trone, Jeanne Mendell, Guy Gammon

Clin Pharmacol Drug Dev· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Jianke Li, Martin Kankam, Denise Trone, Guy Gammon

Br J Clin Pharmacol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML.
Jorge E Cortes, Martin S Tallman, Gary J Schiller, Denise Trone, Guy Gammon

Blood· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Jorge Cortes, Alexander E Perl, Hartmut Döhner, Hagop Kantarjian, Giovanni Martinelli, Guy Gammon

Lancet Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
Brenda M Sandmaier, Samer Khaled, Betül Oran, Guy Gammon, Denise Trone

Am J Hematol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
Mark B Faries, Nicola Mozzillo, Mohammed Kashani-Sabet, John F Thompson, Mark C Kelley, Guy Gammon

Ann Surg Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia.
Madhu Sanga, Joyce James, Joseph Marini, Guy Gammon, Christine Hale

Xenobiotica· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Todd M Cooper, Jeannette Cassar, Elena Eckroth, Jemily Malvar, Richard Sposto, Guy Gammon

Clin Cancer Res· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
Jorge E Cortes, Hagop Kantarjian, James M Foran, Darejan Ghirdaladze, Mamia Zodelava, Guy Gammon

J Clin Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.
Eddy C Hsueh, Richard Essner, Leland J Foshag, David W Ollila, Guy Gammon

J Clin Oncol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Donald L Morton, Eddy C Hsueh, Richard Essner, Leland J Foshag, Steven J O'Day, Guy Gammon

Ann Surg· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
Steven J O'Day, Peter D Boasberg, Lawrence Piro, Timothy S Kristedja, He-Jing Wang, Guy Gammon

Clin Cancer Res· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis